Newsroom Voices Saniona begins 2022 with three clinical trials ongoing January 4, 2022 | Source BioStock The Potential Of Ion Channel-Based Therapeutics September 8, 2021 | Source Cell & Gene Saniona – FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity August 19, 2021 | Source Health Professional Radio [ENG] Saniona’s CEO on progress in 2020 and the way forward May 6, 2021 | Source BioStock Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock Why I Prioritized Patient Advocacy When Building Saniona February 8, 2021 | Source LinkedIn Saniona’s CCO on the Importance of Communication February 4, 2021 | Source BioStock Saniona's CEO on the plans for 2021 January 12, 2021 | Source BioStock Saniona’s chairman aims to recruit America’s best talents October 20, 2020 | Source BioStock Studio
Saniona begins 2022 with three clinical trials ongoing January 4, 2022 | Source BioStock The Potential Of Ion Channel-Based Therapeutics September 8, 2021 | Source Cell & Gene Saniona – FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity August 19, 2021 | Source Health Professional Radio [ENG] Saniona’s CEO on progress in 2020 and the way forward May 6, 2021 | Source BioStock Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock Why I Prioritized Patient Advocacy When Building Saniona February 8, 2021 | Source LinkedIn Saniona’s CCO on the Importance of Communication February 4, 2021 | Source BioStock Saniona's CEO on the plans for 2021 January 12, 2021 | Source BioStock Saniona’s chairman aims to recruit America’s best talents October 20, 2020 | Source BioStock Studio
Saniona – FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity August 19, 2021 | Source Health Professional Radio [ENG]
Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome March 4, 2021 | Source BioStock
